Training & Education in Massachusetts

BioSensics is a wearable sensor and digital health technology company founded in 2007 by three Harvard University scientists. The company specializes in developing FDA-registered medical devices and digital biomarkers for clinical trials, remote patient monitoring, and health assessments, particularly for older adults and neurological disorders. BioSensics' core offerings include advanced fall detection and prevention systems with automatic fall alert capabilities, continuous monitoring of fall risk and physical activity, balance and gait assessment technologies, and cognitive function monitoring sensors. The company also provides the BioDigit Home platform, a centralized data aggregation system that integrates data from various digital health technologies. BioSensics has licensed its fall detection technology to major retailers and medical device manufacturers and provides comprehensive operational and technical services for clinical research across therapeutic areas including Alzheimer's disease, Parkinson's disease, and stroke. With over $50 million in NIH funding support, BioSensics has established itself as a leader in objective measurement of disease symptoms and validated biomarkers for clinical and research applications.

Guldmann North America is a specialized provider of safe patient handling and mobility solutions for healthcare environments. Founded in 1980 and headquartered in Tampa, Florida with offices in Medford, Massachusetts, the company delivers ceiling hoists, mobile lifters, patient slings, and comprehensive accessories designed for emergency care, intensive care, operating rooms, rehabilitation, and long-term care settings. Guldmann emphasizes early mobilization protocols that improve patient recovery outcomes while reducing caregiver injury risk through ergonomic design. Beyond equipment, the company offers integrated services including project consultancy, installation, training in safe patient handling techniques, and on-site support. With a global distributor network spanning Iceland to Australia and substantial service capabilities, Guldmann positions itself as one of the world's largest providers of ceiling hoist system installation and maintenance, serving hospitals, care facilities, and home care environments.

Boyd Biomedical is a biomedical device commercialization partner specializing in the design, manufacturing, and market launch of innovative medical devices. The company serves medical device innovators, startups, and established manufacturers seeking end-to-end support from concept through commercialization. Boyd Biomedical operates through three integrated service lines: Design by Boyd transforms complex biomedical concepts into manufacturable, market-ready devices with superior functionality and intuitive user experiences; Build by Boyd delivers consistent manufacturing quality at competitive costs, supporting both first-product launches and established product scaling; and Launch by Boyd provides strategic positioning and brand development for medical devices targeting investors, clinicians, procurement teams, and patients. The company functions as a partner to biomedical innovators navigating regulatory strategy, design controls, manufacturing scale-up, and market positioning. Boyd Biomedical provides expert analysis and actionable insights through its Knowledge Center, offering case studies, articles, videos, and interviews with founders and executives who have successfully brought breakthrough innovations to market. The firm addresses the critical execution gap between innovation and successful commercialization, positioning itself as a strategic partner for medical device companies seeking to improve their odds of market success and regulatory approval.

Voiant is a clinical trial imaging Contract Research Organization (CRO) specializing in AI-powered imaging solutions for biopharmaceutical companies. With over 30 years of clinical expertise, Voiant delivers high-quality imaging endpoint data and endpoint adjudication services supporting therapies across oncology, ophthalmology, and respiratory indications from Phase I-IV global trials. The company operates a proprietary, purpose-built AI platform that accelerates imaging processing and analysis while maintaining scientific accuracy through expert human oversight. Voiant's services include independent reading center operations, blinded imaging review (BICR), and specialized imaging biomarker analysis. The company has expanded AI capabilities through acquisition of Voxeleron and maintains a global network of subspecialty-trained clinical readers, regulatory expertise, and over 2,700 registered clinical trial sites. Voiant has contributed to multiple FDA-approved therapies and serves as a trusted partner for sponsors, CROs, and clinical research organizations seeking reliable, reproducible imaging endpoint data and faster turnaround times.